BiomimX Applications - Microbiome
Elucidate gastrointestinal microbiome interaction at patient specific level
The Challenge
Fully understand and exploit microbiome for therapeutic use.
A better investigation of the role of the human microbiome in different contexts, such as inflammation, immunology and cancers still remain of paramount importance to effectively implement therapeutic strategies based on its manipulation. Current studies on microbiome-host molecular interactions based on animal models suffer for interspecies differences, limiting their human relevance, and impair an efficient assessment of patient-specific responses.
BiomimX's Solution
Exploit complex human models to elucidate the role of microbiome to get insights for discovery and development of therapeutic solutions.
BiomimX’s uBeat® powered solutions offer the possibility to assess the gut microbiota interaction within a human intestinal compartment, unlocking a biologically relevant tool to acquire data that better translate to the clinics. Our solution can accelerate the discovery and development of microbiome-related therapies and can be exploited to stratify patient response towards more informed design of clinical trials.
Microbiome interaction
Assess the microbiome interaction with intestinal barriers in uGut model, by focusing on epithelium-endothelium specific biomarkers and microbial factors expression.
uGut is a 3D model of the gastrointestinal tract encompassing functional epithelial and endothelial barriers of the intestine, by recapitulating the organ peristaltic-like movement. uGut is able to predict the patient-specific clinical outcome of immune checkpoint inhibitors therapies based on fecal microbiota’s transplantation, highlighting its capability to be used as prognostic tools to better design therapeutic interventions.
Take Advantage from our uBeat® based solution
- Rely on pre-clinical data generated in human relevant models of complex physiology and pathology to boost your discovery phase.
- Elucidate the mode of action of microbiome-based therapeutics and the patient specific responses to better design subsequent clinical phases.